stockrow
Friday 6 November 2026
Export LFCR’s income statement to Excel — free account
Lifecore Biomedical, Inc.
LFCR Healthcare Drug Manufacturers Specialty & Generic
Lifecore Biomedical, Inc.’s revenue for fiscal 2025 (year ended May 2025) was $128.9 million, roughly unchanged from fiscal 2024.
- Revenue
- −18.6%
- EPS
- −1,700.0%
- Free cash flow
- +27,684.0%
- Total debt
- +15.3%
Quarter to September 2026, against a year earlier
6.37
0.03
−0.47%
Follow LFCR
Alert me
| Sep '26 From the 10-Q filed 4 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
4 | 3 | 3 | — |
+8 more TTM periods Free account |
| 178.69% | 201.15% | 293.76% | 0.00% | ||
| (32.36%) | (19.32%) | (17.13%) | 0.00% | ||
ROIC |
0.00% | (2.80%) | (2.32%) | 0.00% | |
Return on Tangible Assets |
(40.61%) | (24.16%) | (21.79%) | 0.00% | |
Average Days of Receivables |
0.00 | 92.96 | 58.22 | 0.00 | |
Free Cash Flow per Share |
0.30 | 0.04 | 0.54 | — | |
Free Cash Flow |
11.22 | 1.48 | 20.05 | — | |
Capital Expenditures |
— | (4.55) | (0.27) | — | |
| Other line items | |||||
Cash ROIC |
1,478.13% | 0.68% | 10.59% | 0.00% | |
Accounts Receivable Turnover |
0.00 | 4.33 | 5.06 | 0.00 | |
Accounts Payable Turnover |
8.84 | 9.91 | 11.53 | 0.00 | |
Inventory Turnover |
2.69 | 2.95 | 2.91 | 0.00 | |
Average Days of Payables |
37.93 | 31.44 | 29.15 | 0.00 | |
Days of Inventory on Hand |
122.33 | 106.32 | 117.01 | 0.00 | |
Tax Rate |
0.01 | 0.02 | 0.02 | — | |
Research and Development Expense of Revenue |
5.39% | 5.59% | 5.95% | — | |
Selling, General and Administrative Expense of Revenue |
27.31% | 28.16% | 28.47% | — | |
Share Based Compensation of Revenue |
3.10% | 3.51% | (1.53%) | — | |
Interest Coverage |
— | (0.30) | (0.21) | — | |
Operating CF/Net income |
(0.15) | (0.13) | (0.51) | — | |
Depreciation/Fixed assets |
0.00 | 0.04 | 0.00 | 0.00 | |
Capex/Depreciation |
— | (0.95) | (1.72) | — | |
Revenue per Share |
3.01 | 3.18 | 3.25 | — | |
Operating CF per Share |
0.30 | 0.16 | 0.54 | — | |
Capex per Share |
0.00 | (0.12) | (0.01) | — | |
Capex to Sales |
0.00 | 0.04 | 0.00 | — |
Columns are period end dates · fundamentals updated 4 Nov 2026